Form FWP Carvana Auto Receivables Filed by: Carvana Receivables Depositor LLC
FREE WRITING PROSPECTUS Dated September 16, 2021 |
|
Filed Pursuant to Rule 433 Registration No. 333-239650 Registration No. 333-239650-07 |
|
Carvana Auto Receivables Trust 2021-P3
Issuing Entity
Carvana Receivables Depositor LLC
Depositor
Carvana, LLC
Sponsor
The Depositor has filed with the Securities and Exchange Commission (SEC) a preliminary prospectus dated September 16, 2021, which describes the notes to be issued by the Issuing Entity. You should review the preliminary prospectus in its entirety before deciding to purchase any of the notes.
Ratings
The Depositor expects that the following classes of notes issued by the Issuing Entity will receive at least the indicated credit ratings from the nationally recognized statistical rating organizations, or rating agencies, listed below.
Class |
Kroll Bond Rating Agency, LLC |
S&P Global Ratings | ||
A-1 |
K1+ (sf) |
A-1+ (sf) | ||
A-2 | AAA (sf) | AAA (sf) | ||
A-3 | AAA (sf) | AAA (sf) | ||
A-4 | AAA (sf) | AAA (sf) | ||
B | AA+ (sf) | AA (sf) | ||
C | A+ (sf) | A (sf) | ||
D | BBB+ (sf) | BBB (sf) |
It is a condition to the issuance of the notes that, on the closing date, each class of notes receive at least the ratings listed above.
BNP PARIBAS |
Citigroup |
Wells Fargo Securities |
Credit Suisse |
Deutsche Bank Securities |
Co-Manager
Baird
STATEMENT REGARDING THIS FREE WRITING PROSPECTUS
The Depositor has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Depositor has filed with the SEC for more complete information about the issuer, the Depositor and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Depositor, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling 1-800-854-5674.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Health researchers can now use SAS to analyze one of the world's most diverse biomedical data sets
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!